Skye Bioscience Inc (SKYE)
5.53
+0.21
(+3.95%)
USD |
NASDAQ |
Nov 14, 16:00
5.53
0.00 (0.00%)
After-Hours: 20:00
Skye Bioscience Net Income (Quarterly): -3.898M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -3.898M |
| June 30, 2024 | -7.903M |
| March 31, 2024 | -5.020M |
| December 31, 2023 | -4.420M |
| September 30, 2023 | -24.95M |
| June 30, 2023 | -3.112M |
| March 31, 2023 | -5.168M |
| December 31, 2022 | -9.892M |
| September 30, 2022 | -3.127M |
| June 30, 2022 | -3.419M |
| March 31, 2022 | -3.043M |
| December 31, 2021 | -2.513M |
| September 30, 2021 | -1.825M |
| June 30, 2021 | -2.024M |
| March 31, 2021 | -2.160M |
| December 31, 2020 | -1.502M |
| September 30, 2020 | -1.297M |
| June 30, 2020 | -1.420M |
| March 31, 2020 | -2.342M |
| December 31, 2019 | 4.852M |
| September 30, 2019 | -4.931M |
| June 30, 2019 | 15.91M |
| March 31, 2019 | -14.77M |
| December 31, 2018 | -6.222M |
| September 30, 2018 | -2.096M |
| Date | Value |
|---|---|
| June 30, 2018 | -2.662M |
| March 31, 2018 | -8.214M |
| December 31, 2017 | -0.6282M |
| September 30, 2017 | -0.4801M |
| June 30, 2017 | -0.7028M |
| March 31, 2017 | -1.283M |
| December 31, 2016 | -1.120M |
| September 30, 2016 | -0.9453M |
| June 30, 2016 | 0.5731M |
| March 31, 2016 | -1.685M |
| December 31, 2015 | -0.6912M |
| September 30, 2015 | -1.183M |
| June 30, 2015 | -2.057M |
| March 31, 2015 | -0.9102M |
| December 31, 2014 | -1.703M |
| September 30, 2014 | -0.8585M |
| July 31, 2014 | 0.0078M |
| April 30, 2014 | -0.0135M |
| January 31, 2014 | 0.0036M |
| October 31, 2013 | -0.0052M |
| July 31, 2013 | -0.0007M |
| April 30, 2013 | 0.0021M |
| January 31, 2013 | 0.0002M |
| October 31, 2012 | 0.0047M |
| July 31, 2012 | 0.0001M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-24.95M
Minimum
Sep 2023
4.852M
Maximum
Dec 2019
-4.209M
Average
-3.077M
Median
Net Income (Quarterly) Benchmarks
| Oramed Pharmaceuticals Inc | 9.212M |
| Viking Therapeutics Inc | -24.94M |
| NovaBay Pharmaceuticals Inc | -1.212M |
| Palatin Technologies Inc | -8.250M |
| iBio Inc | -7.778M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.522M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 93.99M |
| Earnings Yield | -15.15% |
| Normalized Earnings Yield | -8.487 |